Paraneoplastic Syndromes in Patients with Cancer of the Larynx and Hypopharynx

2007 ◽  
Vol 116 (7) ◽  
pp. 502-513 ◽  
Author(s):  
Alfio Ferlito ◽  
Alessandra Rinaldo
Keyword(s):  
Cancer Patients ◽  
Malignant Tumor ◽  
World Literature ◽  
Paraneoplastic Syndromes ◽  
Malignant Neoplasms ◽  
Patients With Cancer ◽  
The World ◽  
Symptoms And Signs

Paraneoplastic syndromes may be the first sign of a malignancy. They are systemic, nonmetastatic manifestations associated with a variety of malignant neoplasms and occurring in a minority of cancer patients. These associations of symptoms and signs are not directly related to the site or local manifestations of a malignant tumor or its metastases, but their recognition may facilitate the detection of malignancies or recurrences. Paraneoplastic syndromes are categorized into 6 types: Dermatologic or cutaneous, endocrine, hematologic, neurologic, osteoarticular or rheumatologic, and ocular. Different oncotypes have rarely been associated with paraneoplastic syndromes in patients with cancer of the larynx and hypopharynx. The world literature has been reviewed.

scholarly journals Vaccination against SARS-COV‑2 in oncology

2021 ◽  
Vol 16 (2) ◽  
pp. 70-80
Author(s):  
A. A. Polyakov ◽  
V. V. Lunin ◽  
F. M. Abbaysbeyli ◽  
O. L. Timofeeva ◽  
V. B. Larionova ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Information Search ◽  
World Literature ◽  
Hematological Malignancies ◽  
Web Of Science ◽  
Careful Monitoring ◽  
Hematopoietic Stem ◽  
Patients With Cancer ◽  
Increased Risk ◽  
The Moment

The objective of the study a detailed, systematic review of the world literature data, which includes all aspects of recommendations for vaccination against SARS-COV‑2 in cancer patients.Materials and methods. Information search was carried out in PubMed, MedLine, Scopus, Web of Science, RSCI.The work included data from literature and information sources that were published before February 2021.Results. The data of retrospective and prospective clinical studies are analyzed. This paper reflects considerations and recommendations for the vaccination of cancer patients by Russian and foreign specialists in the context of COVID‑19 pandemic. The review presents current recommendations for vaccination against SARS-COV‑2 in patients with solid tumors, hematological malignancies, recipients of hematopoietic stem cells and cell therapy.Conclusion. To date, groups at increased risk of infection with the new coronavirus have been identified. These groups include patients with cancer. The presence of tumor does not allow a delay in start of therapy, and requires careful monitoring and observation. In this regard, despite the pandemic, the treatment of cancer patients must be continued regardless of the circumstances. Cancer patients should not be deprived of the opportunity to be vaccinated against SARS-COV‑2. Every patient should be decided individually. At the moment, there are no officially approved recommendations for vaccination against SARS-COV‑2 for cancer patients. Before the creation and approval of final recommendations for cancer patients, it is necessary to focus on compliance with sanitary and anti-epidemic measures and the prevention of COVID‑19 infection. The global cancer community continues to actively develop recommendations for the optimal vaccination against SARS-COV‑2 in cancer patients.The most relevant ones are outlined in this article.

Tripe palms and malignancy.

1989 ◽  
Vol 7 (5) ◽  
pp. 669-678 ◽  
Author(s):  
P R Cohen ◽  
M E Grossman ◽  
L Almeida ◽  
R Kurzrock
Keyword(s):  
Gastric Carcinoma ◽  
World Literature ◽  
Acanthosis Nigricans ◽  
Patients With Cancer ◽  
The World ◽  
Associated Malignancy ◽  
Diagnostic Work ◽  
Work Up ◽  
Pulmonary Tumors ◽  
Diagnostic Work Up

Tripe palms are characterized clinically by thickened velvety palms with pronounced dermatoglyphics. We describe two patients with triple palms and pulmonary tumors, and review the 77 patients with idiopathic- and malignancy-associated tripe palms reported in the world literature. The majority (94%) of published cases of tripe palms occurred in patients with cancer; only five patients showed no evidence of an associated malignancy. Tripe palms were frequently seen in conjunction with acanthosis nigricans (77% of cases), although they can occur alone (23% of cases). In cancer patients with tripe palms alone, the most common underlying neoplasm was pulmonary carcinoma (53% of cases), whereas patients with both tripe palms and acanthosis nigricans frequently had gastric (35% of cases) or pulmonary (11% of cases) carcinomas. A wide variety of other solid tumors have also been observed. Importantly, in over 40% of patients, tripe palms were the presenting feature of a previously undiagnosed malignancy. Therefore, all patients with tripe palms should be evaluated with a full diagnostic work-up for an associated malignancy, particularly lung or gastric carcinoma.

scholarly journals Analysis of the availability and direction of improvement of medical care for patients with malignant neoplasms in the Moscow region

2018 ◽  
Vol 5 (4) ◽  
pp. 106-117
Author(s):  
E. Yu. Ogneva ◽  
A. N. Gurov ◽  
M. V. Pirogov ◽  
E. V. Gameeva ◽  
O. Yu. Aleksandrova
Keyword(s):  
Medical Care ◽  
Cancer Patients ◽  
Russian Federation ◽  
Federal District ◽  
Moscow Region ◽  
High Tech ◽  
Malignant Neoplasms ◽  
Patients With Cancer ◽  
The Subject ◽  
The Russian Federation

Purpose. Carrying out medical and statistical analysis of morbidity and mortality of the population with malignant neoplasms, development of proposals for greater accessibility and areas of improvement of specialized including high-tech medical care (HTMC) for patients with cancer in the Moscow region.Materials and methods. The analysis of morbidity and mortality of the population of the Moscow region from malignant neoplasms and the organization of specialized, including high-tech, medical care to cancer patients on the basis of forms of Federal state statistical observations in relation to the three-level system of the organization of medical care to the population of the region with identification of organizational and financial problems.Results. The incidence of malignant neoplasms in the Moscow region in 2017 amounted to 364.9 per 100 thousand population, which is 1.0% below the level of 2016-365.9 per 100 thousand population and below the average for the Central Federal district and the Russian Federation. The mortality rate from neoplasms in the Moscow region decreased in 2017 to 174.7 cases per 100 thousand population, which is less than the average for the Central Federal district — 207.1 and the Russian Federation — 196.9 per 100 thousand population. At the same time, the volume of specialized medical care (including high — tech medical care) for malignant tumors, in a 24-hour hospital is more than twice the average Russian standard — 13% for SMC and 50% for HTMC. Exceeding the standard of medical care is mainly due to the HTMC 2, which is not planned in the subject of the Russian Federation and is usually in Federal clinics. The share of oncological medical care received outside the medical organizations of the MR is 16%, which exceeds the share of medical care in all other profiles received outside the Moscow region (12%). This situation contributes to the availability of cancer care to the population of the Moscow region.Conclusion. The performed work allowed to draw conclusions that in normative legal acts of Federal level it is necessary to define separately the standard of volumes of specialized, including hi-tech medical care, on the profile of Oncology. Large volumes of HTMC cannot be an unambiguous characteristic of the availability of medical care in General, since HTMC is medical care with the use of complex methods of diagnosis and treatment in clinically complex cases. Large volumes of HTMC can be a consequence of the complexity of clinical cases, but also a consequence of neglect of the disease due to the lack of diagnosis and treatment in the provision of primary health care (PHC) at the 1st level. In the Moscow region, there is a need to redistribute the volume of this medical care not only to cancer dispensaries, but also to other medical organizations. After that, there is a need for the distribution of patients, taking into account the morbidity in the territories, the place of residence of citizens, and taking into account the capabilities of medical organizations for the treatment of cancer patients (surgical treatment, chemotherapy, radiotherapy). Medical organizations of the subject of the Federation shall be ranked taking into account the applied technologies and opportunities of drug therapy. As a result, a clear routing of patients with cancer should be developed in the subject of the Russian Federation.

scholarly journals Neutropenia and management of cancer patients during the COVID-19 pandemic

2021 ◽  
Vol 4 (2) ◽  
pp. 11-13
Author(s):  
O.V. Ponomariova ◽  
P.V. Petelskyi ◽  
A.S. Kasianenko ◽  
T.A. Horbatiuk ◽  
M.M. Nosko ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Point Of View ◽  
Malignant Neoplasms ◽  
Treatment Regimens ◽  
Patients With Cancer ◽  
Long Run ◽  
Number Of Publications ◽  
The One ◽  
Many Sources ◽  
Cancer Network

The COVID-19 pandemic has significantly affected the management of patients with cancer. Due to the quarantine restrictions imposed to some extent around the world, it was necessary to modify treatment regimens by reducing the number of sessions of chemotherapy and radiation therapy, as well as by postponing surgery. The volume of cancer screening has also been reduced. All this, from our point of view, in the long run may not have a very positive effect on the course of treatment and prognosis of cancer. Therefore, doctors today are constantly faced with the task of maintaining the effectiveness of treatment of malignant neoplasms, on the one hand, and reducing the risk of coronavirus — on the other, because, according to many sources, cancer patients are at risk of adverse COVID-19 course. This is especially true for patients with chemotherapy-induced neutropenia. In this article we wanted to demonstrate the latest approaches to the management of cancer patients in this difficult period. We also considered the options for wider use of granulocyte colony-sti­mulating factors to prevent neutropenia in the COVID-19 era. It is still controversy about this in the medical scientific community. Unfortunately, the data available today are not enough to make unambiguous statements about a particular patient management, but by analyzing the large number of publications made during the pandemic year, as well as updated National Comprehensive Cancer Network guidelines, we were able to answer most of the questions that interest us.

scholarly journals Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.

1997 ◽  
Vol 44 (1) ◽  
pp. 109-112 ◽  
Author(s):  
M Rucińska ◽  
M Furman ◽  
Z Skrzydlewski ◽  
E Zaremba
Keyword(s):  
Blood Serum ◽  
Cancer Patients ◽  
Malignant Tumor ◽  
Clinical Stage ◽  
Healthy People ◽  
Colorectal Cancers ◽  
Patients With Cancer ◽  
Healthy Control ◽  
Cancer Procoagulant ◽  
Radical Removal

Activity of cancer procoagulant (CP) was studied in blood serum of 90 patients with cancer of lung, breast, oesophagus and colorectum, and of 15 healthy people. The activity of CP was determined by the coagulation method. Sera of patients with cancer showed higher mean activity of CP than sera of healthy control. Of the 90 cancer patients 78 were identified correctly by this test as having cancer (sensitivity 85%). In the case of lung and colorectal cancers the higher CP activity was observed the more advanced was the clinical stage of cancer, and the test was positive in 100%. After radical removal of malignant tumor of lung, decreased CP activity was found.

scholarly journals IMPACT OF THE COVID-19 PANDEMIC ON THE ONCOLOGICAL PRACTICE

2020 ◽  
Vol 19 (3) ◽  
pp. 5-22 ◽  
Author(s):  
A. D. Kaprin ◽  
E. V. Gameeva ◽  
A. A. Polyakov ◽  
A. L. Kornietskaya ◽  
N. A. Rubtsova ◽  
...  
Keyword(s):  
Cancer Patients ◽  
World Literature ◽  
Web Of Science ◽  
Treatment Options ◽  
Current Data ◽  
Course Of Disease ◽  
Increased Risk ◽  
The World ◽  
The Impact ◽  
Oncological Practice

Detailed, systematic review of the world literature data, including all aspects that reflect the impact of the COVID-19 pandemic on the oncological practice was conducted. The information sources were taken from Pubmed, MedLine, Scopus, Web of Science, and RSCI systems. The data from retrospective and prospective clinical trials have been analyzed. This review presents current data on the impact of COVID-19 on cancer patients, mortality and prognosis of cancer patients infected with COVID-19, treatment options for COVID-19, as well as the case report of the cancer patient with rare atypical COVID-19 course of disease. To date, the groups of increased risk of being infected with a new coronavirus have been identified. These groups include cancer patients. Despite the pandemic, treatment of cancer patients must be continued, since the presence of a tumor process does not allow the therapy to be delayed. The world cancer community is actively continuing to develop recommendations for optimal management of cancer patients in the context of the pandemic. The most relevant of them are described in this article.

scholarly journals COVID-19 in Immunosuppressed and Cancer Patients: A review

2020 ◽  
Vol 5 (S1) ◽  
pp. 69-73
Author(s):  
Shirin Haghighat ◽  
Mehdi Dehghani
Keyword(s):  
Risk Factor ◽  
High Risk ◽  
Cancer Patients ◽  
Severe Disease ◽  
Review Article ◽  
Epidemic Spread ◽  
Patients With Cancer ◽  
The World ◽  
Novel Coronavirus ◽  
The Impact

The rapidly spreading outbreak of infection by novel coronavirus 2 (SARS-CoV-2) from Wuhan, China around the world has started since December 2019. Since the epidemic spread of this infection, individuals with comorbidities are at high risk of severe disease and increased rate of mortality. As patients with cancer are considered immunosuppressed caused by some host and treatment factors, a more detailed investigation on the impact of cancer on COVID-19 outcome seems to be necessary. This review article provides data on cancer patients affected by SARS-CoV-2 infection. Although underlying immunosuppression has not proven as a risk factor for severe COVID-19 infection, most authors have identified cancer patients as a highly vulnerable population. We need more detailed especially randomized studies to compare the outcome of cancer and non-cancer patients with SARS-CoV-2 infection. The more precise studies would help oncologists to make the best decision in cancer therapy.  

scholarly journals ASSESSMENT OF QUALITY OF RENDERING PALLIATIVE CARE TO THE ONCOLOGY PATIENTS

2017 ◽  
Vol 20 (7) ◽  
pp. 177-187
Author(s):  
E.P. Gladunova
Keyword(s):  
Palliative Care ◽  
Malignant Neoplasms ◽  
Medical Assistance ◽  
Oncology Patients ◽  
Patients With Cancer ◽  
The World ◽  
Oncological Diseases ◽  
Prevalence Of Cancer ◽  
Palliative Patients

The analysis of prevalence of cancer in the world, in Russia and on the territory of the Samara Region. The results of analysis of neglect of oncological diseases in the Samara region; the results of regression analysis of growth of oncological diseases are presented. The organization of rendering palliative care in the Samara Region is studied and assessment of provision of palliative patients with berths is carried out. The estimate of provision of patients with malignant neoplasms with drugs for pain management. Factors that reduce the quality of rendering of medical assistance to the oncology patients are revealed. Directions of improving the quality of pharmaceutical care of patients with cancer are suggested.

scholarly journals FEATURES OF DENTAL STATUS IN PATIENTS WITH CANCER

2019 ◽  
Vol 15 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Ольга Успенская ◽  
Ol'ga Uspenskaya ◽  
Ирина Фадеева ◽  
Irina Fadeeva
Keyword(s):  
Oral Cavity ◽  
Cancer Patients ◽  
Mucous Membrane ◽  
Clinical Manifestations ◽  
The Body ◽  
Dental Status ◽  
Malignant Neoplasms ◽  
Patients With Cancer ◽  
Periodontal Tissues ◽  
Dental Diseases

Subject. In the modern world, the prevalence of cancer is growing every year, in this regard, this pathology is one of the most pressing problems in medicine. There is no doubt that malignant neoplasms have a complex interaction with the body. The General mechanisms of occurrence and progression of the tumor process are intensively studied, and to date, a huge amount of material on molecular and clinical Oncology has been accumulated, it is used in related disciplines. The most important sections of dentistry are the diagnosis and treatment of diseases of the mucous membrane. Often, clinical manifestations in the oral cavity are one of the first symptoms indicating a General somatic disease. This article covers the study of the dental status of patients with different localizations of cancer. Objective ― to study the incidence of dental diseases of patients with cancer. Methodology. To conduct a study medical examination of patients with different localizations of cancer was held to determine dental: the definition of DMF-Index, PMA-index, Parodontal Index, and the condition of the mucous membrane of the oral cavity and periodontal tissues. Cancer patients receiving chemotherapy and radiation therapy, patients who refused to participate in the survey were excluded from the survey. Results. The study included 526 patients. The predominance of certain types of dental diseases among patients with a particular cancer pathology was revealed. Conclusions. Our study showed that all patients had decompensated forms of caries. The most common dental diseases combined with cancer are hyperplasia filiform papillae (K14.3), the "geographic" language (K14.1). Periodontal disease occurred in 69,5 % of cases among cancer patients.

Hemangioma of Maxilla

1973 ◽  
Vol 82 (2) ◽  
pp. 254-256 ◽  
Author(s):  
K. L. Sawhney ◽  
P. B. Rao ◽  
Vanaja Sankaran
Keyword(s):  
World Literature ◽  
Axial Skeleton ◽  
X Ray ◽  
Presenting Symptoms ◽  
The World ◽  
Definitive Surgery ◽  
Symptoms And Signs

Bony hemangiomas, while occurring with some frequency in the axial skeleton, are rare in the maxilla. A case is described bring the total in the world literature to 12. Presenting symptoms and signs can include a pulsatile cheek mass, bruit, and toothache. If conventional x-ray reveals a honeycomb effect and resorption of bone, angiography may establish the diagnosis preoperatively. Maxillectomy is probably the treatment of choice. Biopsy is fraught with danger, and should only be undertaken at the time of definitive surgery.

Sign in / Sign up

Export Citation Format

Share Document